Institution statistics

MERCK SHARP & DOHME CORP -  

Ranking results:

Past rankings:
2019
Total Number of Projects:800-900
Networking Rank (Reputation):> 1000
2018
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 10
As coordinator: 0
As participant: 10
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 8.290.694 0 1
2019 0 35.830.196 0 4
2018 0 4.498.931 0 1
2017 0 15.549.833 0 2
2016 0 14.553.750 0 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
PFIZER LIMITED8
NOVARTIS PHARMA7
F HOFFMANNLA ROCHE6
JANSSEN PHARMACEUTICA NV5
ELI LILLY AND COMPANY LIMITED4
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT4
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN4
NOVO NORDISK4
SANOFIAVENTIS4
UCB BIOPHARMA4
BAYER AKTIENGESELLSCHAFT3
EUROPEAN PATIENTS' FORUM3
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES3
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT3
ACADEMISCH ZIEKENHUIS GRONINGEN2
AMGEN LIMITED2
ASTRAZENECA AB2
BAYER PHARMA2
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG2
COVANCE LABORATORIES2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
EUROPEAN CANCER PATIENT COALITION2
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE2
FOLKEHELSEINSTITUTTET2
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE2
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE2
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER2
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE2
KATHOLIEKE UNIVERSITEIT LEUVEN2
LUNDS UNIVERSITET2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY2
THE UNIVERSITY OF LIVERPOOL2
UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANSUNIVERSITAT2
UNIVERSITAIR MEDISCH CENTRUM UTRECHT2
UNIVERSITY OF NEWCASTLE UPON TYNE2
UPPSALA UNIVERSITET2
VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV2
A PERSIDIS & SIA OE1
ABBVIE1
ABBVIE DEUTSCHLAND GMBH & CO KG1
ABBVIE INC1
ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH1
ACADEMISCH ZIEKENHUIS LEIDEN1
ACTELION PHARMACEUTICALS1
AGENZIA ITALIANA DEL FARMACO1
ALCEDIAG1
ALEXION SERVICES EUROPE SPRL1
ALZHEIMER EUROPE1
AMGEN1
ANTAROS MEDICAL AB1
ARTEEVO TECHNOLOGIES1
ASOCIACION NACIONAL EMPRESARIAL DE LA INDUSTRIA FARMACEUTICA1
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1
ASTELLAS PHARMA EUROPE BV1
ASTRAZENECA1
BIOMERIEUX1
BIOSCI CONSULTING BVBA1
BIOXYDYN LIMITED1
BLUEBIRD BIO INC1
BRUKER BIOSPIN MRI1
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL1
CELGENE MANAGEMENT SARL1
CENTRE DE RECHERCHES MEDICALES DE LAMBARENE1
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE1
CHALMERS TEKNISKA HOEGSKOLA AB1
CHARITE UNIVERSITAETSMEDIZIN BERLIN1
CSL BEHRING1
DIMOKRITIO PANEPISTIMIO THRAKIS1
DYNAMIC421
EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG BEVOLKERUNGSSCHUTZ UND SPORT1
EKON MODELING SOFWARE SYSTEMS LTDEKON1
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM1
ERASMUS UNIVERSITEIT ROTTERDAM1
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS1
EUROPEAN AIDS TREATMENT GROUP EV1
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL1
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION1
FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU1
FEDERAAL KENNISCENTRUM VOOR DE GEZONDHEIDSZORG1
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V1
FUJIFILM CELLULAR DYNAMICS INC1
FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU1
FUNDACIO SANT JOAN DE DEU1
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA1
GE HEALTHCARE LIMITED1
GLAXOSMITHKLINE BIOLOGICALS1
GOETEBORGS UNIVERSITET1
GRUNENTHAL1
H LUNDBECK AS1
HEALTH IQ LIMITED1
HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL SOCIETY1
HOSPITAL DO ESPIRITO SANTO DE EVORA EPE1
ICETA INSTITUTO DE CIENCIAS TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO1
IHE INSTITUTET FOR HALSO OCH SJUKVARDSEKONOMI AKTIEBOLAG1
IMPRENSA NACIONAL CASA DA MOEDA S A1
INSTITUT DE RECHERCHES SERVIER1
INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD1
INSTITUTO TUMORI ""GIOVANNI PAOLO II""1
INTE:LIGAND SOFTWARE ENTWICKLUNGS UND CONSULTING1
Constancy:

Total number of partners:250

Partner loyalty:
Frequent Partner: (> 2 projects): 62
Rare Partner: 188

Frequent / Rare Partner Ratio: 0.33

Diversity:

Subjects:
Subject:No:
Diversity index:0
Categories:
Category:No:

Project overview:

Start dateProjectacronymrolefundingpartners
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69428
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-03-01Neurotoxicity De-Risking in Preclinical Drug Discovery NeuroDeRiskparticipant5.331.00018
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2019-01-01Vaccines and Infectious Diseases in the Ageing PopuLation VITALparticipant5.499.88224
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 IB4SD-TRISTANparticipant12.000.00021
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068 VSV-EBOPLUSparticipant8.553.75011
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum